Premium
BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY
Author(s) -
Bazarbachi A.,
Boumendil A.,
Finel H.,
Mohty M.,
Castagna L.,
Blaise D.,
Peggs K.,
Afanasyev B.,
DiezMartin J.,
Corradini P.,
Socié G.,
Robinson S.,
GutiérrezGarcía G.,
Bonifazi F.,
YakoubAgha I.,
Gülbas Z.,
Bloor A.,
Delage J.,
Esquirol A.,
Malladi R.,
Scheid C.,
Ghesquières H.,
Montoto S.,
Dreger P.,
Sureda A.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_71
Subject(s) - brentuximab vedotin , medicine , salvage therapy , transplantation , oncology , chemotherapy , lymphoma , hematopoietic cell , hematopoietic stem cell transplantation , surgery , chemotherapy regimen , hodgkin lymphoma , haematopoiesis , stem cell , biology , genetics